Corcept Therapeutics [CORT] vs Regeneron [REGN] Detailed Stock Comparison

Corcept Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Corcept Therapeutics Inc. wins in 6 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Corcept Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 56.37 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 7.38 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 0.94 9.51 Corcept Therapeutics Inc.
PEG Ratio -2.72 -4.80 Corcept Therapeutics Inc.
EV/EBITDA 96.45 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 13.09% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 2.22% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) 2.22% 23.13% Regeneron Pharmaceuticals, Inc.
Return on Equity 15.02% 14.86% Corcept Therapeutics Inc.
Return on Assets (TTM) 3.34% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $141.79M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 18.34% 15.66% Corcept Therapeutics Inc.
Price-to-Sales Ratio (TTM) 6.36 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $4.43B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 5.82 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 98.74% 84.95% Corcept Therapeutics Inc.
Revenue per Share (TTM) $7 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $0.80 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.25 0.40 Corcept Therapeutics Inc.
Short % of Float 15.76% 2.55% Regeneron Pharmaceuticals, Inc.

Corcept Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

CORT
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Corcept Therapeutics Inc.0.25%13.35%47.45%158.30%-4.79%117.59%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Corcept Therapeutics Inc.18.34%258.45%268.49%1,470.27%1,767.34%1,698.48%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Corcept Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCORTREGN
Market Information
Market Cap i$4.84B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,059,913642,495
90 Day Avg. Volume i1,702,484617,765
Last Close$83.12$614.98
52 Week Range$28.66 - $91.00$503.25 - $821.11
% from 52W High-8.66%-25.10%
All-Time High$117.33 (Mar 31, 2025)$1,211.20 (Aug 26, 2024)
% from All-Time High-29.16%-49.23%
Growth Metrics
Quarterly Revenue Growth0.11%0.03%
Quarterly Earnings Growth-0.21%-0.08%
Financial Health
Profit Margin (TTM) i0.13%0.31%
Operating Margin (TTM) i0.02%0.23%
Return on Equity (TTM) i0.15%0.15%
Debt to Equity (MRQ) i0.949.51
Cash & Liquidity
Book Value per Share (MRQ)$6.11$304.65
Cash per Share (MRQ)$3.50$83.86
Operating Cash Flow (TTM) i$142.00M$4.98B
Levered Free Cash Flow (TTM) i$114.19M$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Corcept Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCORT (Apr 22, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i56.3718.00
Forward P/E i28.0514.21
PEG Ratio i-2.72-4.80
Price to Sales (TTM) i6.365.50
Price to Book (MRQ) i7.382.45
Market Capitalization
Market Capitalization i$4.84B$80.98B
Enterprise Value i$4.43B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i5.824.95
Enterprise to EBITDA i96.4516.72
Risk & Other Metrics
Beta i0.250.40
Book Value per Share (MRQ) i$6.11$304.65

Financial Statements Comparison: Corcept Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCORT (2025)REGN (2025)
Revenue/Sales i761.41M14.34B
Cost of Goods Sold i12.98M2.10B
COGS % of Revenue i1.7%14.6%
Gross Profit i748.43M12.24B
Gross Margin i98.3%85.4%
Research & Development i254.91M5.85B
Operating Income (EBIT) i44.80M3.70B
Operating Margin i5.9%25.8%
EBITDA i46.69M5.00B
EBITDA Margin i6.1%34.8%
Pre-Tax Income i66.46M5.23B
Pre-Tax Income % of Revenue i8.7%36.5%
Income Tax i-33.19M725.80M
Income Tax % of Revenue i-4.4%5.1%
Net Income (Profit) i99.65M4.50B
Profit Margin i13.1%31.4%

Balance Sheet & Liquidity Metrics

MetricCORT (2025)REGN (2025)
Cash & Equivalents i120.50M3.12B
Total Current Assets i485.46M18.02B
Total Current Assets % of Revenue i63.8%125.7%
Total Current Liabilities i166.09M4.37B
Total Current Liabilities % of Revenue i21.8%30.5%
Long-Term Debt i5.02M2.71B
Long-Term Debt % of Revenue i0.7%18.9%
Total Shareholders Equity i647.81M31.26B
Retained Earnings i643.39M35.80B
Retained Earnings % of Revenue i84.5%249.6%
Property, Plant & Equipment i6.47M1.54B

Cash Flow Statement Comparison

MetricCORT (2025)REGN (2025)
Operating Cash Flow i160.91M6.30B
Operating Cash Flow % of Revenue i21.1%43.9%
Capital Expenditures i-211,0000
Free Cash Flow i141.79M3.77B
FCF Margin i18.6%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase i0-3.97B

Short Interest & Institutional Ownership Analysis

MetricCORTREGN
Shares Short i12.45M2.55M
Short Ratio i6.684.46
Short % of Float i15.76%2.55%
Shares Outstanding i105.97M105.72M
Float Shares i87.88M98.55M
% Held by Insiders i11.54%1.98%
% Held by Institutions i72.17%91.08%
% Held by Public i16.29%6.94%

Dividend Analysis & Yield Comparison: Corcept Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCORTREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026